Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Jasper Therapeutics, Inc.

NASDAQ: JSPR · Life Sciences · 11 alerts · CIK 1788028

Share price
$11.77Close, Nov 16
Market cap
$13.1M
Shares outstanding
1.11MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Jasper Therapeutics, Inc. filings on SEC EDGAR ↗

8:06 AM ET 10-Q
Financial Results

Jasper Therapeutics Q3 2026 Results: Net Loss of $144M, Loss Widens

Jasper Therapeutics reported a significant net loss of $148.4 million for the nine months ended September 30, 2026, primarily driven by a $129.5 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity through a financing and acquisition, ending the period with $135.3 million in cash and cash equivalents.

Key figure
Net loss $144M
8:01 AM ET 8-K
Financial Results

Jasper Therapeutics Financial Results

Jasper Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update following its acquisition of Kira Pharmaceuticals. The company highlighted progress in its Phase 2 renal basket study for vensobafusp alfa (KP104), including completed enrollment in the IgA nephropathy cohort and the dosing of the first patient with IC-MPGN.

“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).”

Jeet Mahal, President and Chief Executive Officer of Jasper

“We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”

Jeet Mahal, President and Chief Executive Officer of Jasper

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.